Lindbrook Capital, LLC Acadia Pharmaceuticals Inc Transaction History

Lindbrook Capital, LLC

$1.18 Billion
Q3 2024

A detailed history of Lindbrook Capital, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Lindbrook Capital, LLC holds 126 shares of ACAD stock, worth $2,062. This represents 0.0% of its overall portfolio holdings.

Number of Shares

126

Previous 92 36.96%

Holding current value

$2,062

Previous $1,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$15.14 - $19.14 $514 - $650	34 Added 36.96%	126 $1,000
Q2 2024 Jul 31, 2024	SELL	$14.62 - $18.42 $277 - $349	-19 Reduced 17.12%	92 $1,000
Q1 2024 Apr 25, 2024	BUY	$17.79 - $30.86 $35 - $61	2 Added 1.83%	111 $2,000
Q4 2023 Jan 31, 2024	SELL	$20.78 - $31.77 $477 - $730	-23 Reduced 17.42%	109 $3,000
Q3 2023 Oct 25, 2023	BUY	$20.84 - $33.47 $500 - $803	24 Added 22.22%	132 $2,000
Q2 2023 Jul 28, 2023	BUY	$17.8 - $25.65 $284 - $410	16 Added 17.39%	108 $2,000
Q4 2022 Jan 24, 2023	SELL	$14.2 - $18.63 $4,316 - $5,663	-304 Reduced 76.77%	92 $0
Q3 2022 Nov 10, 2022	BUY	$14.11 - $18.27 $3,753 - $4,859	266 Added 204.62%	396 $6,000
Q2 2022 Aug 01, 2022	SELL	$13.01 - $27.22 $481 - $1,007	-37 Reduced 22.16%	130 $2,000
Q1 2022 Apr 21, 2022	BUY	$20.94 - $27.5 $1,423 - $1,870	68 Added 68.69%	167 $4,000
Q3 2021 Nov 05, 2021	BUY	$15.78 - $24.77 $1,562 - $2,452	99 New	99 $2,000
Q2 2021 Jul 27, 2021	SELL	$19.4 - $27.42 $1,261 - $1,782	-65 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$25.02 - $54.99 $1,326 - $2,914	53 Added 441.67%	65 $2,000
Q4 2020 Jan 27, 2021	BUY	$41.04 - $56.79 $492 - $681	12 New	12 $1,000

Others Institutions Holding ACAD

# of Institutions

280

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.65B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Account

Lindbrook Capital, LLC Acadia Pharmaceuticals Inc Transaction History